Avid Bioservices, Inc, a biologics contract development and manufacturing company, focuses on the development and current Good Manufacturing Practices (cGMP) manufacture of biopharmaceutical products derived from mammalian cell culture. It provides a range of process development, cGMP clinical, and commercial manufacturing services for the biotechnology and biopharmaceutical industries.
Read More…
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Phone714-508-6100
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$53.60 million
Profitability
Miscellaneous
Employees185
Next Earnings Date12/9/2019 (Estimated)
OptionableOptionable
Avid Bioservices (NASDAQ:CDMO) Frequently Asked Questions
What is Avid Bioservices' stock symbol?
Avid Bioservices trades on the NASDAQ under the ticker symbol "CDMO."
When did Avid Bioservices' stock split? How did Avid Bioservices' stock split work?
Avid Bioservices's stock reverse split on Monday, July 10th 2017. The 1-7 reverse split was announced on Friday, July 7th 2017. The number of shares owned by shareholders was adjusted after the market closes on Friday, July 7th 2017. An investor that had 100 shares of Avid Bioservices stock prior to the reverse split would have 14 shares after the split.
How were Avid Bioservices' earnings last quarter?
Avid Bioservices Inc (NASDAQ:CDMO) announced its earnings results on Thursday, September, 5th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.03) by $0.05. The biopharmaceutical company had revenue of $15.25 million for the quarter, compared to the consensus estimate of $14.37 million. Avid Bioservices had a negative net margin of 9.63% and a negative return on equity of 11.89%. The business's quarterly revenue was up 21.1% compared to the same quarter last year. View Avid Bioservices' Earnings History.
When is Avid Bioservices' next earnings date?
What guidance has Avid Bioservices issued on next quarter's earnings?
Avid Bioservices issued an update on its FY 2020 earnings guidance on Thursday, September, 5th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $64-67 million, compared to the consensus revenue estimate of $65.5 million.
What price target have analysts set for CDMO?
2 brokerages have issued 1 year price targets for Avid Bioservices' stock. Their predictions range from $10.00 to $11.00. On average, they anticipate Avid Bioservices' stock price to reach $10.50 in the next twelve months. This suggests a possible upside of 98.5% from the stock's current price. View Analyst Price Targets for Avid Bioservices.
What is the consensus analysts' recommendation for Avid Bioservices?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Avid Bioservices in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Avid Bioservices.
What are Wall Street analysts saying about Avid Bioservices stock?
Here are some recent quotes from research analysts about Avid Bioservices stock:
- 1. According to Zacks Investment Research, "Avid Bioservices, Inc. is a dedicated contract development and manufacturing organization focused on development and cGMP manufacturing of biopharmaceutical products derived from mammalian cell culture. The company provides process development, high quality cGMP clinical and commercial manufacturing services for the biotechnology and biopharmaceutical industries. It also offer process development activities, including cell line development and optimization, cell culture and feed optimization, analytical methods development and product characterization. Avid Bioservices Inc., formerly known as Peregrine Pharmaceuticals Inc., is based in TUSTIN, United States. " (9/4/2019)
- 2. HC Wainwright analysts commented, "Valuation and impediments to achieving price target. We reiterate our Buy rating with a price target of $11. Our valuation is based on a discounted EBITDA model, which we believe takes into account both the established and anticipated revenue growth of Avid, which is the cornerstone of the company’s business. We assign a 23x multiple on F2023 EBIDTA discounted back at Avid’s WACC of 13%." (7/8/2019)
Has Avid Bioservices been receiving favorable news coverage?
Headlines about CDMO stock have trended negative recently, InfoTrie Sentiment reports. The research group ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores closest to five being the most favorable. Avid Bioservices earned a news impact score of -2.8 on InfoTrie's scale. They also assigned news stories about the biopharmaceutical company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View News Stories for Avid Bioservices.
Are investors shorting Avid Bioservices?
Avid Bioservices saw a increase in short interest in September. As of September 30th, there was short interest totalling 1,950,000 shares, an increase of 6.6% from the August 30th total of 1,830,000 shares. Based on an average trading volume of 297,500 shares, the short-interest ratio is presently 6.6 days. Currently, 3.5% of the company's stock are sold short. View Avid Bioservices' Current Options Chain.
Who are some of Avid Bioservices' key competitors?
Some companies that are related to Avid Bioservices include Turning Point Therapeutics (TPTX), Enanta Pharmaceuticals (ENTA), Radius Health (RDUS), Zymeworks (ZYME), Innoviva (INVA), ArQule (ARQL), Theravance Biopharma (TBPH), Esperion Therapeutics (ESPR), Gossamer Bio (GOSS), Dicerna Pharmaceuticals (DRNA), TherapeuticsMD (TXMD), AnaptysBio (ANAB), Amphastar Pharmaceuticals (AMPH), Epizyme (EPZM) and Odonate Therapeutics (ODT).
What other stocks do shareholders of Avid Bioservices own?
Who are Avid Bioservices' key executives?
Avid Bioservices' management team includes the folowing people:
- Dr. Roger J. Lias, Pres, CEO & Director (Age 59)
- Mr. Mark R. Ziebell, VP, Gen. Counsel & Corp. Sec. (Age 55)
- Mr. Daniel R. Hart, Chief Financial Officer (Age 46)
- Mr. Stephen Michael Hedberg, Sr. Director of Fin. & SEC Reporting and Principal Financial & Accounting Officer (Age 44)
- Ms. Lorna Larson, Sr. Director of HR
How do I buy shares of Avid Bioservices?
Shares of CDMO can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Avid Bioservices' stock price today?
One share of CDMO stock can currently be purchased for approximately $5.29.
How big of a company is Avid Bioservices?
Avid Bioservices has a market capitalization of $297.50 million and generates $53.60 million in revenue each year. The biopharmaceutical company earns $-4,220,000.00 in net income (profit) each year or ($0.17) on an earnings per share basis. Avid Bioservices employs 185 workers across the globe.View Additional Information About Avid Bioservices.
What is Avid Bioservices' official website?
How can I contact Avid Bioservices?
Avid Bioservices' mailing address is 2642 Michelle Drive Suite 200, TUSTIN CA, 92780. The biopharmaceutical company can be reached via phone at 714-508-6100 or via email at [email protected]
MarketBeat Community Rating for Avid Bioservices (NASDAQ CDMO)
MarketBeat's community ratings are surveys of what our community members think about Avid Bioservices and other stocks. Vote "Outperform" if you believe CDMO will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CDMO will underperform the S&P 500 over the long term. You may vote once every thirty days.
